Ethos Discovery is a 501(c)3 nonprofit organization devoted to delivering innovations that will improve the outcome for pets and humans afflicted with complex medical problems. Ethos Veterinary Health, LLC formed Ethos Discovery to conduct nonprofit scientific research to advance veterinary and human medical science in December 2016. Ethos Discovery is headed by Drs. Chand Khanna and Keith Richter.
The scientific strategy of Ethos Discovery focuses on identifying areas of unmet need through the optics of clinical teams within Ethos Veterinary Health. The leadership of Ethos Discovery aligns these needs with academic and institutional nonprofit and commercial collaborators around the world. Subsequent clinical studies are expected to deliver information to serve these unmet needs, and thus determine the value of these novel opportunities.
These efforts will begin in the area of oncology (i.e. cancer research), but will expand to deliver innovations to all fields of veterinary medicine and surgery. As a scientific incubator, Ethos Discovery will conduct clinical studies that include pet animals with naturally occurring disease such as cancer. The goals of these studies will be to determine the value of these research findings for future use in animals and/or in humans with complex medical problems. Clinical studies will seek to answer basic questions about the value of these research findings, and in so doing, we expect to derive novel diagnostic and therapeutic opportunities for both pets and human patients.
Ethos Discovery will offer results from our studies free of charge, and without restriction, to parties interested in commercialization for human health. In doing so, the work of Ethos Discovery will develop and deliver scientific innovations to both humans and pets.
One hundred percent of the Organization’s time is allocated to the achievement of the Organization’s tax-exempt purpose.
Ethos Discovery acts as an incubator of scientific innovations to address unmet diagnostic and therapeutic needs identified through the optics of Ethos Veterinary Health. These needs will be aligned with the innovation platforms of a variety of academic and other research institutions around the world.
The similarity of disorders in pets and humans is widely recognized. It is likely the innovations we are working on will be useful for human patients in the future. In all cases Ethos Discovery will disclose these advances free of charge, and without restriction, to the public and to groups interested in the commercialization of these findings for use in human medical care.
Ethos Discovery will evaluate novel therapeutic and diagnostic approaches for cancer in pets with naturally occurring cancer, rather than in conventional preclinical models of cancer (i.e., the mouse in which cancer was induced or artificially created).
For the benefit of human health care, Ethos Discovery will also provide data to the Comparative Oncology Program of the National Cancer Institute, an organization that is widely recognized for its leadership in the inclusion of pet animals with cancer in the development of new human cancer therapies.
In the event that these potential innovations can be useful for future veterinary patients, Ethos Discovery will enter into agreements allowing Ethos Veterinary Health the right of first refusal to pursue commercialization of these potential innovations for veterinary patients.